Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Growth Factors Identified for Current Orphan Drug Market

By BiotechDaily International staff writers
Posted on 08 Jul 2013
A new market research report by Kalorama Information (Rockville, MD, USA) identifies factors likely to have stimulated the current orphan drug market, with further growth expected for the next forecast period.

Drugs for treating rare conditions are commonly referred to as "orphan drugs." The global orphan drug market reached 61 billion in 2012, according to Kalorama. The new Kalorama report - "The World Market for Orphan Drugs" - states that the increasing incidence of diseases affecting the aged will drive the market to increase at a rate of 11.5% throughout the forecast period, reaching USD 105.2 billion by 2017. In the USA, the largest market, Congress determined that adequate therapies for many rare diseases had not been developed because companies could not expect an orphan drug to make sufficient profit; therefore, incentives were needed for developing such drugs. According to Kalorama, these incentives have worked, helping to create a thriving market for this sector of treatments.

The report breaks out the market by company and by category. Non-Hodgkin's lymphoma, multiple myeloma, renal disease, and osteoporosis are among the diseases where treatments are not sufficient, according to the report. "In these markets regulators have allowed new orphan therapies," said Bruce Carlson, publisher, Kalorama Information, "Pharmaceutical companies have seen an opportunity in developing drugs with reduced regulatory costs and incentivized development."

Kalorama's estimate relates to the market where only orphan drug-designation revenue is included. Other estimates may also include brand revenue not truly occurring from an orphan designation. A product available as an orphan drug in one country may be available under traditional marketing approval in another. Some products that gain orphan status are later granted approval and removed from the orphan drug database at the developer's request. Factors involved in also include reimbursement, regulation, disease status, and general development, all of which were taken into account in Kalorama's study.

The report also presents major and small pharmaceutical companies' activities within this drug category, their market share, and predicts leading market contributers.

Related Links:
Kalorama Information
Kalorama Orphan Drugs Report


Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.